Kronos Bio Stock News

California State Teachers Retirement System grew its position in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 136.6% during the second quarter, HoldingsChannel reports. The institutional investor owned 53,517 shares of the companys stock after buying an additional 30,898 shares during the quarter. California State Teachers Retirement Systems holdings in Kronos Bio were worth $1,282,000 as []

Nuveen Asset Management LLC raised its position in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 203.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 161,915 shares of the companys stock after purchasing an additional 108,487 shares during the quarter. Nuveen Asset Management LLC []

Squarepoint Ops LLC acquired a new stake in Kronos Bio, Inc. (NASDAQ:KRON) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 28,137 shares of the companys stock, valued at approximately $674,000. Squarepoint Ops LLC owned approximately 0.05% of Kronos Bio at the []

Preliminary clinical data from Phase 1/2 study still anticipated in Q4 Preliminary clinical data from Phase 1/2 study still anticipated in Q4

Announced FDA clearance of Investigational New Drug application (IND) for lanraplenib (LANRA) for treatment of patients with acute myeloid leukemia (AML)

Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients

Kronos IPO'd in October.

MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in t

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced t

Positive End-of-Phase 2 meeting with the FDA for entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced t

Registrational Phase 3 trial will assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint to support potential accelerated approval

KB-0742 generated using the company's proprietary small molecule microarray (SMM) screening platform

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced pa